The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
12-Jul-21
Pending
$1.7 billion
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Target:
Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Acquiror:
KPS Capital Partners
Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America
04-Oct-16
$223 million
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Target:
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
23-Oct-03
$3.1 billion
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Target:
Debenhams plc
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Acquiror:
Baroness Retail (a consortium of CVC, TPG and Merrill Lynch)
Advised the independent committee of the Board of Directors of Debenhams plc, a leading UK department store chain, with regards to the sale of the company